For most of the last two decades, a young adult diagnosed with IgA nephropathy heard a version of the same conversation: control your blood pressure, take a blood pressure medication that also protects the kidneys, watch your protein levels, and hope. Roughly half of patients progressed to kidney failure.
That conversation has changed faster in the past nine months than in the previous twenty years. The FDA approved atacicept, sold as Trutakna, on July 7, 2026, following the approval of sibeprenlimab in late 2025. Two additional drugs now sit before the agency with decisions expected before the end of December.
